In the clinical management of severe asthma, biological agents (such as anti-IgE antibodies, anti-IL-5/IL-5R antibodies, etc.)are key therapeutic approaches targeting specific inflammatory phenotypes, particularly T2 inflammation. This evidence concerns the gene IL5 and asthma.